AngioDynamics (NASDAQ:ANGO) CFO Stephen Trowbridge Sells 1,720 Shares of Company Stock

AngioDynamics, Inc. (NASDAQ:ANGO) CFO Stephen Trowbridge sold 1,720 shares of AngioDynamics stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $12.17, for a total transaction of $20,932.40. Following the sale, the chief financial officer owned 304,076 shares in the company, valued at $3,700,604.92. This represents a 0.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

AngioDynamics Stock Down 2.9%

NASDAQ:ANGO opened at $11.99 on Friday. The stock’s 50 day moving average price is $14.18 and its 200 day moving average price is $12.47. The company has a market capitalization of $504.23 million, a PE ratio of -15.37 and a beta of 0.30. AngioDynamics, Inc. has a 52-week low of $9.39 and a 52-week high of $16.29.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. The company had revenue of $80.92 million for the quarter, compared to analyst estimates of $80.51 million. AngioDynamics had a negative net margin of 10.12% and a negative return on equity of 4.49%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, sell-side analysts anticipate that AngioDynamics, Inc. will post -0.26 EPS for the current fiscal year.

Hedge Funds Weigh In On AngioDynamics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Pinnacle Wealth Planning Services Inc. acquired a new stake in AngioDynamics during the third quarter worth about $40,000. Integrated Wealth Concepts LLC purchased a new position in shares of AngioDynamics in the 2nd quarter worth about $38,000. Legal & General Group Plc acquired a new position in shares of AngioDynamics in the 2nd quarter valued at about $45,000. Public Employees Retirement System of Ohio acquired a new position in shares of AngioDynamics in the 2nd quarter valued at about $64,000. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of AngioDynamics by 0.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 758,450 shares of the medical instruments supplier’s stock worth $8,624,000 after purchasing an additional 5,509 shares during the period. 89.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a report on Thursday, October 15th. Wall Street Zen cut AngioDynamics from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $20.00 price target on shares of AngioDynamics in a research note on Friday, October 9th. HC Wainwright reduced their price objective on shares of AngioDynamics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, October 13th. Finally, Zacks Research raised shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company that develops and manufactures minimally invasive devices used in vascular access, peripheral vascular disease treatment, oncology and surgical procedures. Its products are designed to support physicians in diagnosing and treating patients while reducing the need for more invasive interventions.

The company’s portfolio includes the Auryon system for atherectomy and thrombectomy procedures, the NanoKnife system, which uses irreversible electroporation technology for the ablation of certain soft-tissue tumors, and devices for vascular access and the management of procedure-related complications.